Navigation Links
Fitch Raises Boston Scientific's Rating Outlook to Positive
Date:5/19/2009

NATICK, Mass., May 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that Fitch Ratings has raised the Company's rating outlook to positive from stable, while affirming the Company's corporate credit rating at BB+.

Fitch said the revised rating outlook reflects:

  • The success the Company has had in stabilizing its drug-eluting stent (DES) business and returning its cardiac rhythm management (CRM) business to growth, which has included the launch of a number of new DES and CRM products. Fitch noted that the Company's other businesses have been performing well.

  • The Company's restructuring program, which is nearly completed and is expected to provide a lower cost structure going forward.

  • The Company's paying down approximately $1.3 billion in debt during the last four quarters.

  • The Company's research and development efforts, which are expected to provide a relatively steady stream of new product introductions across Boston Scientific's entire business.

"The Fitch upgrade is further testimony to the progress we are making in strengthening our financial fundamentals and driving profitable sales growth," said Sam Leno, Executive Vice President and Chief Financial Officer of Boston Scientific. "It comes as additional welcome news after the March upgrades from Moody's and Standard and Poor's. We will continue working to improve our profit margins, free cash flow, debt repayment and financial discipline."

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial position and discipline, new product introductions, debt repayment and cost-savings initiatives, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696 (office)
              Investor Relations
              Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fitch Affirms ProAssurances Rating and Stable Outlook
2. Years of Heavy Smoking Raises Heart Risks
3. President Obama Praises Retailers as Part of the Health Care Solution
4. NCPA Briefing Raises Questions About Trustees Annual Report
5. Impulsivity Raises Alcoholism Risk
6. Walk Raises Almost $200,000 to Heighten Brain Tumor Awareness
7. Chronic Kidney Disease Raises Risk for Some Cancers
8. Questions Grow as World Health Organization Raises Pandemic Alert for Swine Flu to Level Five
9. WHO Raises Swine Flu Alert
10. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
11. Economic Downturn Raises Anxiety and Depression Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... The health insurance industry is ... (AEP) and the Open Enrollment Period (OEP). 2016 was no exception. If anything, ... witnessing higher deductibles, rising premiums, and few choices with their insurance, which is ...
(Date:1/24/2017)... ... , ... The Cruise Web Inc. was recognized today as Northeast ... Annual MSC True Partnerships’ Awards. , The 2016 MSC True Partnerships Awards are ... on overall business growth in revenue and guests and continuous partnership support and innovative ...
(Date:1/24/2017)... ... January 24, 2017 , ... OMI Industries, a worldwide leader ... distribution partnership with Byers Scientific & Manufacturing , a leading designer, engineer ... agreement, OMI Industries formulated a special version of Ecosorb® for Byers Scientific & ...
(Date:1/24/2017)... Hill, N.C. (PRWEB) , ... January 24, 2017 ... ... Trump Administration is the focus of a new report from the Frank ... Kenan-Flagler Business School. , Influential business leaders, academics and policy makers identified concrete ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: January 23, 2017 ... the nation’s foremost water advocate and host of the nationally syndicated The Sharon ... America, once again welcomed one of her favorite guests and colleagues, Dr. Gerald ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Md. , Jan. 24, 2017   Intrexon Corporation ... engineering and industrialization of biology to improve the quality of ... has entered into a definitive agreement to acquire GenVec, ... and pioneer in the development of AdenoVerse™ gene delivery technology.  ... GenVec,s expertise in adenoviral vectors and cGMP drug product manufacturing ...
(Date:1/24/2017)... , Jan. 24, 2017   QR ... biopharmaceutical company developing novel therapies for the treatment ... announced the appointment of four world-class key opinion ... new appointments join QR Pharma,s previous roster of ... and direction to support the development of the ...
(Date:1/24/2017)... Research and Markets has announced the addition of the "Optogenetics ... report to their offering. ... Global Optogenetics Market is poised to grow at ... approximately $76.24 million by 2025. Some of the prominent ... using optogentic techniques for neurosciences, quick growth ultrafast laser tools technology, ...
Breaking Medicine Technology: